What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2023-03-31 compared with 2022-03-31 · 18 added, 18 removed, 33 unchanged (52% of the section changed)

2 unchanged sentences

of March 13, 2023, we had 258 record holders of our common stock.

This number does not include the number of persons whose

shares are in nominee or in “street name” accounts through brokers.

This number does not include the number of persons whose shares are

in nominee or in “street name” accounts through brokers.

did not pay dividends during 2022 or 2021.

4 unchanged sentences

if any, legal restrictions on the payment of dividends and other factors that our board of directors deems relevant.

the Company has announced its decision to issue shares of Impact BioMedical, Inc.

to its shareholders of record at a to be determined

the Company has announced its decision to issue shares of Impact BioMedical, Inc., a wholly-owned subsidiary of the Company, to its shareholders of record at a to be determined

record date that will correspond with the registration of Impact BioMedical’s common stock.

The Company announced that it intended

to issue four (4) shares of Impact BioMedical stock for each share of DSS common stock held by DSS shareholders (with the exception of

shares beneficially held by Alset International Ltd).

to issue four (4) shares of Impact BioMedical stock for each share of DSS common stock held by DSS shareholders.

Authorized for Issuance Under Equity Compensation Plans

1 unchanged sentence

and Consultant Equity Incentive Plan (the “Plans”) is as follows:

stock to be issued upon vesting

of securities to be issued upon exercise of outstanding options, warrants and rights

average exercise price of outstanding options, warrants and rights

of securities

available for

issuance (under

Equity compensation plans approved by security

2013 Employee,

Director and Consultant Equity Incentive Plan - options

2013 Employee, Director

and Consultant Equity Incentive Plan - warrants

Restricted stock to be issued upon vesting

Number of securities to be issued upon exercise of outstanding options, warrants and rights

Weighted average exercise price of outstanding options, warrants and rights

Number of securities

remaining available for

issuance (under equity compensation

Plans (excluding

securities reflected in

column (a & b))

Plan Category

Equity compensation plans approved by security holders

2013 Employee, Director and Consultant Equity Incentive Plan - options

2013 Employee, Director and Consultant Equity Incentive Plan - warrants

2021 Employee, Director and Consultant Equity Incentive Plan

16 unchanged sentences

Repurchased by the Registrant

did not purchase or repurchase any of our securities in the fiscal year ended December 31, 2021, including the fourth quarter.

did not purchase or repurchase any of our securities in the fiscal year ended December 31, 2022.

6 - SELECTED FINANCIAL DATA

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity